European Commission logo
English English
CORDIS - EU research results
CORDIS

Boosting Ethionamide efficacy and lowering the dose with a small molecule transcriptional modulators, to overcoming MDR-TB infections and define a new place for Ethionamide in 1st-line TB treatments.

Intellectual Property Rights

NOVEL COMPOUNDS

Application/Publication number: 20 18072143
Date: 2018-08-15
Applicant(s): BIOVERSYS AG

NOVEL COMPOUNDS

Application/Publication number: 20 18072145
Date: 2018-08-15
Applicant(s): GLAXOSMITHKLINE INVESTIGACION Y DESARROLLO SL

NOVEL COMPOUNDS

Application/Publication number: 20 18072143
Date: 2018-08-15
Applicant(s): GLAXOSMITHKLINE INVESTIGACION Y DESARROLLO SL

NOVEL COMPOUNDS

Application/Publication number: 20 18072145
Date: 2018-08-15
Applicant(s): BIOVERSYS AG

NOVEL COMPOUNDS

Application/Publication number: 20 18072143
Date: 2018-08-15
Applicant(s): BIOVERSYS AG

NOVEL COMPOUNDS

Application/Publication number: 20 18072145
Date: 2018-08-15
Applicant(s): BIOVERSYS AG

NOVEL COMPOUNDS

Application/Publication number: 20 18072144
Date: 2018-08-15
Applicant(s): GLAXOSMITHKLINE INVESTIGACION Y DESARROLLO SL

NOVEL COMPOUNDS

Application/Publication number: 20 18072144
Date: 2018-08-15
Applicant(s): BIOVERSYS AG

NOVEL COMPOUNDS

Application/Publication number: 20 18072145
Date: 2018-08-15
Applicant(s): GLAXOSMITHKLINE INVESTIGACION Y DESARROLLO SL

NOVEL COMPOUNDS

Application/Publication number: 20 18072144
Date: 2018-08-15
Applicant(s): BIOVERSYS AG

NOVEL COMPOUNDS

Application/Publication number: 20 18072143
Date: 2018-08-15
Applicant(s): GLAXOSMITHKLINE INVESTIGACION Y DESARROLLO SL

Searching for OpenAIRE data...

There was an error trying to search data from OpenAIRE

No results available